IX Biopharma Ltd Annual General Meeting 2025: Resolutions Passed, Director Re-Appointments, and Shareholder Updates

Director Re-Appointments:

Mr. Albert Ho Shing Tung and Mr. Teo Woon Keng John were re-appointed as directors under retirement by rotation, with overwhelming 99.92% approval. Their continuity can provide stability in governance and strategic direction.

Directors’ Fees for FY2026: Approval was given for directors’ fees up to S\$334,000 for the year ending 30 June 2026, to be paid quarterly in arrears.
Investor Note: No opposition to remuneration could indicate shareholder satisfaction with current board performance and compensation.

Re-Appointment of Auditors: Messrs BDO LLP was re-appointed as the Company’s auditors, with the board authorised to fix their remuneration. This ensures continuity in audit oversight, a key factor for investor confidence.

Share Issuance Authority:

The board received authority to allot and issue shares up to 100% of issued share capital, with up to 50% on a non pro-rata basis, subject to SGX-ST regulations.
Potential Price Sensitivity: This broad mandate gives the board flexibility for capital raising, mergers, or acquisitions, which could materially affect share dilution and market perception.

Employee Incentive Schemes:

Approval for the issuance of shares under the iX Employee Share Option Scheme and iX Performance Share Plan, with a cap at 15% of total issued shares (excluding treasury shares and subsidiary holdings).
Investor Note: The ability to issue shares for employee incentives may impact future share supply and potentially dilute existing holdings. However, such plans are typically used to align employee interests with shareholder value creation.

IX Biopharma Ltd Annual General Meeting 2025: Resolutions Passed, Director Re-Appointments, and Shareholder Updates

View IX BiopharmaW260718 Historical chart here

Related Posts

Keppel DC REIT Announces Advanced Distribution and Preferential Offering Details for S$1 Billion Equity Fund Raising

Bumitama Agri Reports Strong 9M25 Results with Higher Revenue, Profit, and Production Growth

Versalink Holdings Limited Outlines Strategic Initiatives, Cost Measures, and Diversification Plans in FY2025 Response to SIAS Queries